Journal
NATURE COMMUNICATIONS
Volume 6, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms6909
Keywords
-
Categories
Funding
- National Institutes of Health [AI64350, CA171972, CA58033, AG036690, R21CA164688, U54 CA118948]
- Department of Defense [DOD-W81XWH-10-PCRP-SIDA]
- NIH [P50 CA093990]
- NATIONAL CANCER INSTITUTE [R21CA164688, R01CA171972, P50CA093990, R01CA058033, R01CA155235, R01CA167637, R01CA100302, U54CA118948, U54CA118623, R01CA171277] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064350, R21AI105727] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R01AG036690] Funding Source: NIH RePORTER
Ask authors/readers for more resources
CD24 is overexpressed in nearly 70% human cancers, whereas TP53 is the most frequently mutated tumour-suppressor gene that functions in a context-dependent manner. Here we show that both targeted mutation and short hairpin RNA (shRNA) silencing of CD24 retard the growth, progression and metastasis of prostate cancer. CD24 competitively inhibits ARF binding to NPM, resulting in decreased ARF, increase MDM2 and decrease levels of p53 and the p53 target p21/CDKN1A. CD24 silencing prevents functional inactivation of p53 by both somatic mutation and viral oncogenes, including the SV40 large T antigen and human papilloma virus 16 E6-antigen. In support of the functional interaction between CD24 and p53, in silico analyses reveal that TP53 mutates at a higher rate among glioma and prostate cancer samples with higher CD24 mRNA levels. These data provide a general mechanism for functional inactivation of ARF and reveal an important cellular context for genetic and viral inactivation of TP53.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available